Stock SAGE SAGE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Sage Therapeutics, Inc.

Equities

SAGE

US78667J1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-16 pm EDT 		5-day change 1st Jan Change
15.63 USD +2.02% Intraday chart for Sage Therapeutics, Inc. -5.39% -27.87%
Mar. 26 JPMorgan Raises Price Target on Sage Therapeutics to $29 From $24, Maintains Overweight Rating MT
Mar. 26 Sage Therapeutics, Inc. Announces the Retirement of Steven Paul from the Board CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
BU
JPMorgan Raises Price Target on Sage Therapeutics to $29 From $24, Maintains Overweight Rating
MT
Sage Therapeutics : Announces Dr. Steve Paul to Retire from Board of Directors
PU
Sage Therapeutics, Inc. Announces the Retirement of Steven Paul from the Board
CI
Sage Therapeutics to Present at Upcoming March Investor Conferences
BU
Deutsche Bank Adjust Sage Therapeutics Price Target to $18 From $21, Maintains Hold Rating
MT
Oppenheimer Adjusts Sage Therapeutics Price Target to $25 From $23, Maintains Perform Rating
MT
RBC Raises PT on Sage Therapeutics to $26 From $21, Says Early Metrics From Zurzuvae Launch Suggest Promising Signs; Keeps Sector Perform, Speculative Risk
MT
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
MT
Sage Therapeutics Q4 Net Loss Narrows, Net Product Revenue Declines
MT
Transcript : Sage Therapeutics, Inc., Q4 2023 Earnings Call, Feb 14, 2024
Sage Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (SAGE) SAGE THERAPEUTICS Posts Q4 Revenue $78M, vs. Street Est of $61M
MT
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
BU
Sage Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
BU
Wedbush Adjusts Sage Therapeutics' Price Target to $24 From $22, Keeps Neutral Rating
MT
Sage Therapeutics, Inc. Enters into Lease Agreement with 55 Cambridge Parkway, LLC
CI
Oppenheimer Adjusts Sage Therapeutics Price Target to $23 From $20, Maintains Perform Rating
MT
Transcript : Sage Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 04:30 PM
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SAGE Stock
  4. News Sage Therapeutics, Inc.